Patents by Inventor Mark D. GUSTAVSON

Mark D. GUSTAVSON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • QUANTITATIVE METHODS AND KITS FOR PROVIDING REPRODUCIBLE IHC4 SCORES
    Publication number: 20190391164
    Abstract: The present technology relates generally to determining a risk of recurrence of disease in a cancer patient. In particular, this approach to determining a risk of recurrence involves utilizing standardized quantitative assessments of the level of biomarker expression selected from estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki-67 (Ki67) in a patient's tumor to determine the risk of recurrence, thereby allowing a caretaker to determine the best course of treatment for the patient.
    Type: Application
    Filed: September 6, 2019
    Publication date: December 26, 2019
    Applicant: Novartis AG
    Inventors: Mark D. Gustavson, Jason Christiansen
  • Quantitative methods and kits for providing reproducible IHC4 scores
    Patent number: 10408846
    Abstract: The present technology relates generally to determining a risk of recurrence of disease in a cancer patient. In particular, this approach to determining a risk of recurrence involves utilizing standardized quantitative assessments of the level of biomarker expression selected from estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki-67 (Ki67) in a patient's tumor to determine the risk of recurrence, thereby allowing a caretaker to determine the best course of treatment for the patient.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: September 10, 2019
    Assignee: Novartis AG
    Inventors: Mark D. Gustavson, Jason Christiansen
  • QUANTITATIVE METHODS AND KITS FOR PROVIDING REPRODUCIBLE IHC4 SCORES
    Publication number: 20130310267
    Abstract: The present technology relates generally to determining a risk of recurrence of disease in a cancer patient. In particular, this approach to determining a risk of recurrence involves utilizing standardized quantitative assessments of the level of biomarker expression selected from estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki-67 (Ki67) in a patient's tumor to determine the risk of recurrence, thereby allowing a caretaker to determine the best course of treatment for the patient.
    Type: Application
    Filed: March 15, 2013
    Publication date: November 21, 2013
    Inventors: Mark D. GUSTAVSON, Jason CHRISTIANSEN